Major Strides in HER2 Blockade for Metastatic Breast Cancer

被引：10
作者：
Sharma, Priyanka [1 ]
机构：
[1] Univ Kansas, Med Ctr, Dept Internal Med, Kansas City, KS 66103 USA
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2020年 / 382卷 / 07期
关键词：
TRASTUZUMAB; PERTUZUMAB; DOCETAXEL; SURVIVAL;
D O I：
10.1056/NEJMe1916310
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Breast cancer that is characterized by amplification or overexpression of human epidermal growth factor receptor 2 (HER2) accounts for 15 to 20% of all forms of the disease. The advent of HER2-targeted drugs, such as trastuzumab, pertuzumab, lapatinib, and the antibody-drug conjugate trastuzumab emtansine, has revolutionized the treatment of both early-stage and metastatic HER2-positive breast cancer.(1-4) The increasing availability of HER2-targeted agents has led to improved outcomes for patients with HER2-positive metastatic breast cancer, as reported in a study in which overall survival rose from a median of 38.7 months to 51.1 months from 2008 through 2012.(5) The standard first-line . . .
引用
收藏
页码：669 / 671
页数：3
相关论文
共 50 条
  • [31] Predicting Pathological Complete Response in Neoadjuvant Dual Blockade With Trastuzumab and Pertuzumab in HER2 Gene Amplified Breast Cancer
    Xiao, Yi
    Ding, Jiahan
    Ma, Dachang
    Chen, Sheng
    Li, Xun
    Yu, Keda
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [32] Changes over time of extracellular domain of HER2 (ECD/HER2) serum levels have prognostic value in metastatic breast cancer
    Bramwell, Vivien H. C.
    Doig, Gordon S.
    Tuck, Alan B.
    Wilson, Sylvia M.
    Tonkin, Katia S.
    Tomiak, Anna
    Perera, Francisco
    Vandenberg, Theodore A.
    Chambers, Ann F.
    BREAST CANCER RESEARCH AND TREATMENT, 2009, 114 (03) : 503 - 511
  • [33] Specific blockade of VEGF and HER2 pathways results in greater growth inhibition of breast cancer xenografts that overexpress HER2
    Le, Xiao-Feng
    Mao, Weiqun
    Lu, Chunhua
    Thornton, Angela
    Heymach, John V.
    Sood, Anil K.
    Bast, Robert C., Jr.
    CELL CYCLE, 2008, 7 (23) : 3747 - 3758
  • [34] HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry
    Morsberger, Laura
    Pallavajjala, Aparna
    Long, Patty
    Hardy, Melanie
    Park, Rebecca
    Parish, Rebecca
    Nozari, Azin
    Zou, Ying S.
    CANCER CELL INTERNATIONAL, 2022, 22 (01)
  • [35] Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer
    Ma, Cynthia X.
    Bose, Ron
    Gao, Feng
    Freedman, Rachel A.
    Telli, Melinda L.
    Kimmick, Gretchen
    Winer, Eric
    Naughton, Michael
    Goetz, Matthew P.
    Russell, Christy
    Tripathy, Debu
    Cobleigh, Melody
    Forero, Andres
    Pluard, Timothy J.
    Anders, Carey
    Niravath, Polly Ann
    Thomas, Shana
    Anderson, Jill
    Bumb, Caroline
    Banks, Kimberly C.
    Lanman, Richard B.
    Bryce, Richard
    Lalani, Alshad S.
    Pfeifer, John
    Hayes, Daniel F.
    Pegram, Mark
    Blackwell, Kimberly
    Bedard, Philippe L.
    Al-Kateb, Hussam
    Ellis, Matthew J. C.
    CLINICAL CANCER RESEARCH, 2017, 23 (19) : 5687 - 5695
  • [36] HER2 Signaling in Breast Cancer
    Shin, Incheol
    TRANSLATIONAL RESEARCH IN BREAST CANCER, 2021, 1187 : 53 - 79
  • [37] Real-world effectiveness of dual HER2 blockade with pertuzumab and trastuzumab for neoadjuvant treatment of HER2-positive early breast cancer (The NEOPETRA Study)
    Gonzalez-Santiago, Santiago
    Saura, Cristina
    Ciruelos, Eva
    Luis Alonso, Jose
    de la Morena, Pilar
    Santisteban Eslava, Marta
    Gallegos Sancho, Maria Isabel
    de Luna, Alicia
    Dalmau, Elsa
    Servitja, Sonia
    Ruiz Borrego, Manuel
    Ignacio Chacon, Jose
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 184 (02) : 469 - 479
  • [38] Expert consensus on the clinical diagnosis and targeted therapy of HER2 breast cancer (2023 edition)
    Li, Jianbin
    Wang, Xiaojia
    Wang, Shusen
    Wang, Shu
    Wang, Tao
    Liu, Yueping
    Geng, Cuizhi
    Jin, Feng
    Yin, Yongmei
    Zhang, Qingyuan
    Song, Erwei
    Wu, Jiong
    Jiang, Zefei
    TRANSLATIONAL BREAST CANCER RESEARCH, 2022, 3
  • [39] HER2 in metastatic colorectal cancer: a new to target to remember
    Bitar, Lynn
    Zouein, Joseph
    Haddad, Fady Gh
    Eid, Roland
    Kourie, Hampig R.
    BIOMARKERS IN MEDICINE, 2021, 15 (02) : 133 - 136
  • [40] Pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer
    Kawajiri, Hidemi
    Takashima, Tsutomu
    Kashiwagi, Shinichiro
    Noda, Satoru
    Onoda, Naoyoshi
    Hirakawa, Kosei
    EXPERT REVIEW OF ANTICANCER THERAPY, 2015, 15 (01) : 17 - 26
12345